Industry Symposium: New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond
Supported by Novartis

Friday, October 12, 2018
13:30 – 14:30

 Chairpersons Richard de BoerAustralia                                                                                                                                           Hall B
Belinda Yeo, Australia
13:30 – 13:35 Welcome
Richard de Boer, Australia
Belinda Yeo, Australia
13:35 – 13:55 Role of CDK4/6 Inhibitors in overcoming endocrine resistance: Are they all the same?
Stephen Johnston, UK
13:55 – 14:10 CDK4/6 Inhibitors: The Australian experience, and what to do after progression?
Elgene Lim, Australia
14:10 – 14:30 Case studies and panel discussion